Market Outlook

By 2035, the U.S. IVD Assay Development Market is expected to reach approximately USD 4.40 billion, expanding at a CAGR of 9.10% during the forecast period 2026–2035. The market is estimated at USD 1.84 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

The U.S. IVD assay development industry occupies a critical position between biomarker discovery and commercially deployable diagnostic testing. It encompasses the scientific, analytical, engineering, clinical, regulatory, stability, quality, and commercialization work required to convert a biomarker or diagnostic concept into an assay capable of generating reproducible clinical results. Market demand extends from conventional immunoassays and clinical chemistry tests to increasingly sophisticated molecular diagnostics, multiplex infectious-disease panels, next-generation sequencing assays, oncology companion diagnostics, blood-based biomarker tests, and decentralized point-of-care platforms.

The economic foundation for assay development in the United States is unusually strong. Approximately 14 billion laboratory tests are performed annually across the country, while the Clinical Laboratory Improvement Amendments framework covers roughly 320,000 laboratory entities. This creates a very large installed testing environment in which manufacturers, reference laboratories, health systems, biotechnology companies, pharmaceutical developers, and diagnostic start-ups continuously require new assays, assay modifications, analytical validation, platform transfer, quality documentation, and regulatory support.

The opportunity is becoming more valuable as diagnostic complexity increases. Historically, assay-development economics were heavily influenced by reagent optimization, antibody selection, calibration, analytical sensitivity, specificity, and reproducibility. These remain essential, but premium development programs increasingly require multiplexing, advanced bioinformatics, algorithm development, reference-material qualification, specimen-stability studies, interference analysis, clinical performance validation, automation compatibility, cybersecurity considerations for connected platforms, and documentation suitable for FDA submission.

The U.S. market expanded from an estimated USD 1.33 billion in 2021 to USD 1.70 billion in 2024, supported initially by the unprecedented acceleration of infectious-disease assay development during the pandemic and subsequently by broader investment in molecular diagnostics, respiratory multiplex testing, oncology biomarkers, companion diagnostics, decentralized testing, and chronic-disease screening. The market reached approximately USD 1.84 billion in 2025 as development spending shifted from emergency-response testing toward higher-value diagnostic pipelines with longer commercial lives.

Through 2035, the highest-value growth will increasingly originate from assays that influence a therapeutic or clinical decision rather than simply provide a laboratory measurement. Oncology companion diagnostics, circulating tumor DNA assays, multi-analyte molecular panels, blood-based neurological biomarkers, antimicrobial-resistance assays, multiplex respiratory diagnostics, reproductive-health testing, and personalized treatment-selection assays are moving assay development further into the center of clinical decision-making.

The U.S. market is therefore evolving from a laboratory-development service category into a strategic diagnostic-commercialization ecosystem. Buyers increasingly need partners that can combine assay science, manufacturability, clinical validation, regulatory strategy, quality systems, biostatistics, data interpretation, and technology transfer. Providers capable of supporting an assay from feasibility through FDA-ready commercialization should capture disproportionately higher value during the forecast period.

 

Introduction

According to the U.S. IVD Assay Development Market Report, demand is being shaped by the convergence of diagnostic decentralization, precision medicine, chronic-disease burden, molecular testing, pharmaceutical biomarker strategies, and increasingly sophisticated regulatory expectations.

An in vitro diagnostic assay converts biological information into clinically interpretable information. Depending on the intended use, the assay may identify an infectious organism, detect a genetic alteration, quantify a protein or metabolite, determine treatment eligibility, monitor disease progression, assess therapeutic response, or estimate clinical risk. The commercial success of the final test depends heavily on decisions made during assay development, including biomarker selection, specimen type, reagent architecture, analytical measurement range, controls, calibration, limit of detection, cross-reactivity, reproducibility, workflow design, stability, usability, and integration with the intended instrument.

The United States offers one of the world’s most commercially important environments for this work because diagnostic development is supported by large clinical laboratory networks, major academic medical centers, pharmaceutical and biotechnology research clusters, substantial venture financing, sophisticated hospital systems, specialist physicians, and an established FDA medical-device framework.

The underlying healthcare system provides significant scale. U.S. national health expenditures reached approximately USD 5.3 trillion in 2024, including more than USD 1.6 trillion in hospital spending and approximately USD 1.1 trillion in physician and clinical-services expenditure. Diagnostic testing sits across these expenditure categories because laboratory information influences screening, diagnosis, drug selection, hospital admission decisions, infectious-disease management, oncology treatment, chronic-disease monitoring, and post-treatment surveillance.

Demographics strengthen the long-term testing requirement. The U.S. population aged 65 years and older reached approximately 61.2 million in 2024, representing about 18% of the population. Older populations consume substantially more diagnostic services because cancer, cardiovascular disease, diabetes, neurological disorders, renal disease, and multimorbidity become more common with age.

Cancer represents one particularly important assay-development opportunity. More than 2.04 million new cancer cases were expected in the United States in 2025. The oncology diagnostic pipeline increasingly requires detection of genomic alterations, gene fusions, copy-number changes, protein-expression markers, circulating tumor DNA, methylation patterns, minimal residual disease, and therapy-response biomarkers. This creates development demand across PCR, sequencing, immunohistochemistry, digital pathology, liquid biopsy, and companion diagnostic platforms.

The market also benefits from persistent infectious-disease requirements. More than 2.8 million antimicrobial-resistant infections are estimated to occur in the U.S. each year. Respiratory pathogens additionally create recurring demand for multiplex assays that can differentiate influenza, SARS-CoV-2, RSV, and other pathogens from a single specimen. Instead of returning to a pre-pandemic development model, infectious-disease diagnostics have moved toward preparedness, multiplexing, decentralization, and faster syndromic differentiation.

The commercial objective has consequently changed. Assay developers are no longer optimizing exclusively for laboratory accuracy. They are increasingly asked to optimize for accuracy plus workflow, manufacturability, regulatory risk, turnaround time, cost per reportable result, instrument compatibility, reimbursement potential, and scalability. Those requirements will determine which development organizations gain strategic importance during 2026–2035.

 

Key Market Drivers: What’s Fueling the U.S. IVD Assay Development Market Boom?

The first major driver is the extraordinary volume and clinical importance of laboratory testing in the United States. Billions of tests influence U.S. clinical decisions every year, while approximately 320,000 laboratory entities operate within the CLIA framework. Even small improvements in assay performance, throughput, automation, specimen handling, or interpretation can therefore create substantial economic value once deployed across large laboratory networks.

A second driver is the shift toward precision oncology. Cancer treatment increasingly depends on biomarker-defined patient populations rather than histology alone. Molecular assays are being developed to detect actionable mutations, rearrangements, genomic signatures, microsatellite instability, tumor mutational burden, and other biomarkers that determine whether a patient may benefit from a targeted therapy. As pharmaceutical pipelines fragment cancers into increasingly precise molecular subpopulations, diagnostic development becomes an integrated component of therapeutic commercialization.

Companion diagnostics are especially valuable because an assay can directly determine eligibility for a corresponding therapy. For pharmaceutical sponsors, assay-development quality can consequently influence clinical-trial recruitment, regulatory timing, market access, and the size of the treatable patient population. This creates willingness to invest in premium development partners with expertise in biomarker strategy, clinical validation, FDA interaction, and global assay deployment.

A third driver is the rapid evolution of molecular diagnostics. PCR remains central to clinical molecular testing, but the opportunity is broadening into digital PCR, targeted sequencing, high-plex molecular panels, isothermal amplification, CRISPR-enabled detection, liquid biopsy, and multi-analyte algorithms. These technologies require greater development sophistication than conventional single-analyte tests because performance depends on assay chemistry, specimen preparation, amplification, sequencing or signal detection, software, and interpretation.

A fourth driver is point-of-care and decentralized diagnostic development. Healthcare providers increasingly want testing closer to the patient when a rapid result can change immediate treatment. The value proposition is particularly strong for respiratory infections, sexually transmitted infections, antimicrobial resistance, cardiac markers, coagulation, pregnancy testing, and metabolic assessment. For manufacturers, however, moving an assay from the central laboratory to point-of-care environments creates additional design constraints. Systems must tolerate less experienced operators, limited infrastructure, variable environmental conditions, simplified sample preparation, and stringent usability requirements.

A fifth driver is the disease burden associated with diabetes and metabolic disorders. Approximately 38.4 million Americans are estimated to have diabetes, while a substantially larger population has prediabetes. Glycemic testing is mature, but assay-development opportunities extend into renal complications, cardiovascular-risk markers, endocrine testing, metabolic disease stratification, continuous monitoring validation, and combinations of biomarkers intended to identify disease progression earlier.

A sixth driver is the growth of blood-based diagnostic biomarkers. Blood collection is generally more scalable and accessible than tissue biopsy, cerebrospinal-fluid sampling, or other invasive specimen collection. The FDA’s clearance in 2025 of the first blood-based IVD intended to aid Alzheimer’s disease diagnosis illustrates the direction of the market. Similar innovation is occurring in oncology screening, transplant monitoring, prenatal assessment, autoimmune disease, cardiovascular risk, liver disease, and neurodegeneration.

A seventh driver is U.S. pharmaceutical and biotechnology R&D. Biomarker programs increasingly begin during therapeutic development rather than after a drug has reached the market. Pharmaceutical companies may require prototype assay development, exploratory biomarker testing, clinical-trial assays, bridging studies, companion diagnostic development, central-laboratory deployment, and eventual transfer to a commercial platform. This expands the assay-development revenue opportunity well beyond conventional diagnostic manufacturers.

An eighth driver is regulatory complexity. FDA pathways for IVDs may involve 510(k), De Novo, PMA, or other applicable mechanisms depending on risk and intended use. Higher-risk oncology and treatment-selection assays can require substantial analytical and clinical evidence. Regulatory uncertainty surrounding laboratory-developed tests also reinforced the strategic value of regulatory planning. After the FDA’s 2024 LDT final rule was vacated by a federal district court in March 2025, the agency subsequently restored the relevant regulatory text to its earlier form. For developers, the episode demonstrated that regulatory strategy must remain flexible and cannot be separated from assay-development planning.

Finally, health-system economics favor diagnostics capable of changing costly downstream decisions. A test that avoids an unnecessary therapy, supports earlier cancer detection, identifies a resistant pathogen, reduces emergency-department uncertainty, or accelerates targeted treatment can have economic value far exceeding the price of the assay itself. Development companies able to connect analytical performance to clinical and economic utility will be better positioned to command premium pricing.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. IVD assay development market is increasingly centered on converting complex biological signatures into testing formats that can operate reliably in routine clinical care. The challenge is no longer simply discovering a biomarker. The challenge is building a reproducible commercial assay around that biomarker.

Next-generation sequencing is one of the most strategically important innovation areas. Modern oncology panels may analyze hundreds of genes and multiple variant types within a single workflow. The FDA-approved TruSight Oncology Comprehensive assay, for example, uses targeted NGS to evaluate more than 500 genes while reporting different classes of genomic alterations and tumor profiling information. Development programs of this complexity require substantial work in library preparation, probe design, coverage uniformity, reference standards, variant-calling pipelines, bioinformatics validation, and clinical interpretation.

Integrated sequencing platforms are also compressing the time between specimen processing and actionable genomic results. This is important for community oncology and hospital laboratories where sending specimens to an external reference laboratory can add days to therapeutic decision-making. Assay developers are therefore focusing not only on analytical capability but on end-to-end workflow simplification.

Liquid biopsy is another major innovation frontier. Cell-free DNA and circulating tumor DNA can support genomic profiling, treatment selection, recurrence assessment, and potentially cancer screening. The FDA’s approval of a blood-based colorectal cancer screening assay in 2024 demonstrated the commercial potential of integrating genomic mutations, methylation, and fragmentation patterns into a clinically actionable test. The underlying development challenge is substantial because tumor-derived DNA may represent only a small fraction of circulating DNA, requiring high analytical sensitivity and extensive control of pre-analytical variables.

Neurological biomarker assays are expanding the addressable market further. In 2025, FDA clearance of a blood assay using the pTau217-to-beta-amyloid 1-42 relationship to aid Alzheimer’s diagnosis established an important precedent for less invasive neurological testing. The clinical study used for FDA review included 499 plasma samples, demonstrating how assay development in emerging neurological indications must connect biomarker science with well-defined clinical-reference methods.

Multiplex infectious-disease testing remains another important innovation field. Rather than testing sequentially for individual organisms, laboratories and point-of-care settings increasingly use assays capable of distinguishing multiple pathogens from one specimen. Respiratory multiplex testing is particularly valuable when influenza, SARS-CoV-2, RSV, and other infections produce overlapping symptoms. Development economics favor platforms where new assay menus can be added to an installed instrument base.

Assay automation is also becoming a competitive differentiator. Developers are reducing manual pipetting, reagent preparation, calibration steps, and technologist intervention. This matters because laboratory staffing constraints remain an operational concern throughout the U.S. healthcare system. An assay that produces equivalent clinical performance with fewer manual steps can create a stronger hospital value proposition even when reagent cost is higher.

Artificial intelligence and computational diagnostics are becoming embedded within assay development. Algorithms can support image interpretation, signal normalization, variant classification, multi-marker risk scoring, quality control, and selection of clinically meaningful patterns from high-dimensional datasets. In these products, software validation becomes inseparable from wet-laboratory validation.

Manufacturers are also investing more heavily in reference materials, quality controls, calibrators, and standardized panels. Complex molecular and protein assays require traceable controls that can test the complete analytical process. This creates opportunities for specialist suppliers serving assay developers during feasibility, verification, validation, manufacturing, and post-market quality monitoring.

The next competitive threshold will be development speed without sacrificing evidence quality. Diagnostic companies increasingly need shorter concept-to-commercialization cycles, but regulatory and clinical expectations remain high. Development partners that maintain reusable design controls, validated processes, regulatory templates, automation expertise, biostatistical capability, and established clinical-site networks can reduce development time without transferring unacceptable risk to the sponsor.

 

Segmentation Insights

The U.S. IVD Assay Development Market is segmented on the basis of offering, technology, application, end user, and region.

 

By Offering

IVD Assay Development Services

IVD assay development services represent the largest and strategically most important offering. These programs typically begin with feasibility assessment and may include biomarker selection, antibody or primer screening, reagent optimization, sample-preparation design, analytical sensitivity, specificity, precision, linearity, measuring-range determination, interference testing, reference-range development, and prototype verification.

Demand is rising because diagnostic companies increasingly outsource specialized components of development rather than maintaining every technical capability internally. Small and emerging diagnostic companies use outsourcing to access infrastructure and regulatory expertise without building expensive laboratories. Large manufacturers use external partners to increase pipeline capacity, gain access to specialized technologies, and reduce development bottlenecks.

IVD Assay Stability Testing

Stability testing is expected to remain one of the fastest-growing service categories because assay commercialization requires evidence that reagents, calibrators, controls, cartridges, and finished kits maintain performance through stated storage and transportation conditions.

Development programs may require real-time stability, accelerated stability, freeze-thaw assessment, shipping simulation, open-vial stability, onboard stability, reagent-lot evaluation, and environmental stress testing. The growth of home diagnostics and decentralized testing increases the importance of stability because products may experience less controlled distribution and storage environments than traditional laboratory reagents.

IVD Packaging and Design Transfer Services

Packaging development includes more than graphic design. Assay developers must determine how reagents, controls, consumables, instructions, barcodes, environmental protection, and kit configuration will support reliable use through the full shelf life.

Design transfer becomes especially important when a laboratory-developed prototype must be converted into a repeatably manufactured commercial product. Development partners that can connect assay optimization with manufacturing engineering have an advantage because they can identify scalability problems before regulatory submission or launch.

Regulatory, Validation and Quality Support

Regulatory support is becoming a larger component of assay-development spending. Activities include intended-use strategy, device classification assessment, analytical-validation planning, clinical-study design, FDA interaction support, quality-system documentation, risk management, statistical analysis, submission preparation, and responses to regulator questions.

The value of these services is highest in molecular oncology, companion diagnostics, infectious-disease panels, high-risk screening assays, and products introducing novel biomarkers or intended uses.

Technology Transfer and Custom QA/QC Services

Technology transfer, method transfer, custom quality-control development, verification testing, and post-development technical support represent a smaller but strategically important category. These activities reduce the risk that assay performance achieved in development will deteriorate when the method is transferred to another facility, contract manufacturer, clinical laboratory, or instrument platform.

 

By Technology

Immunoassay and Immunochemistry

Immunoassay remains the largest technology segment because antibodies and antigen-binding systems support a wide range of infectious-disease, endocrine, cardiac, reproductive, oncology, autoimmune, allergy, and neurological tests.

Development is moving toward higher sensitivity, multiplexing, automated immunoassay analyzers, chemiluminescent detection, novel labels, improved antibody-pair selection, and blood-based biomarker applications. Neurological biomarkers represent an especially important emerging opportunity because highly sensitive immunoassays may permit proteins historically measured using cerebrospinal fluid or specialized research techniques to move toward routine blood testing.

Molecular Diagnostics

Molecular diagnostics should record the strongest value expansion through 2035. The segment includes PCR, RT-PCR, multiplex nucleic-acid amplification, digital PCR, isothermal amplification, genotyping, sequencing-based assays, liquid biopsy, and other nucleic-acid technologies.

The commercial advantage of molecular assays is the ability to extract highly specific biological information. In infectious disease, they can identify pathogens and resistance markers. In oncology, they can identify actionable mutations or genomic signatures. In inherited disease, they can identify causative variants. This breadth supports sustained development investment.

Clinical Chemistry and Biochemistry

Clinical chemistry remains a mature but high-volume development category. Assays measure glucose, lipids, enzymes, electrolytes, proteins, metabolites, renal markers, liver markers, and other analytes central to routine medicine.

Growth is driven less by completely new core analytes and more by automation, improved calibration, higher sensitivity, consolidated reagent systems, specialized biomarkers, and integration of chemistry results into multi-marker disease algorithms.

Hematology and Coagulation

Hematology development includes blood-cell analysis, morphology, coagulation, platelet function, hemoglobin analysis, and increasingly software-supported interpretation. Hospitals require reliable, rapid assays because hematology and coagulation frequently influence emergency, surgical, oncology, and intensive-care decisions.

Development priorities include standardized reagents, reduced interference, compact analyzers, point-of-care coagulation, advanced cell classification, and digital morphology.

Microbiology and Urinalysis

Microbiology assay development is being reshaped by antimicrobial resistance and the need for faster pathogen identification. Culture remains clinically important, but molecular identification, resistance-marker detection, mass-spectrometry-enabled workflows, and rapid susceptibility methods are expanding.

Urinalysis remains a high-volume routine category, with development concentrated on automation, strip chemistry, image interpretation, sediment analysis, renal markers, and streamlined point-of-care workflows.

 

By Application

Infectious Diseases

Infectious diseases represent the largest application area for U.S. IVD assay development. Respiratory pathogens, sexually transmitted infections, gastrointestinal pathogens, bloodstream infections, antimicrobial resistance, hepatitis, HIV, healthcare-associated infections, and emerging infectious threats generate persistent development demand.

The market has moved beyond the pandemic-era single-pathogen model. Multiplex assays that differentiate pathogens associated with similar clinical symptoms are becoming increasingly valuable because they can provide more actionable information from a single specimen.

Antimicrobial resistance strengthens this opportunity. With more than 2.8 million antimicrobial-resistant infections occurring annually in the U.S., assays that rapidly identify organisms and resistance mechanisms can support both patient care and antimicrobial stewardship.

Oncology

Oncology is expected to be the fastest-growing major application through 2035. More than two million new cancer diagnoses annually create substantial demand for assays supporting screening, diagnosis, prognosis, therapy selection, recurrence monitoring, and longitudinal disease management.

Development spending is migrating toward multi-gene sequencing, companion diagnostics, liquid biopsy, methylation, minimal residual disease, circulating tumor DNA, protein biomarkers, and multi-analyte risk algorithms. Oncology programs also command premium development economics because regulatory evidence requirements and treatment implications are substantial.

Diabetes and Metabolic Diseases

Diabetes remains a large testing application due to the approximately 38.4 million people in the U.S. estimated to have the disease. Traditional glucose and HbA1c testing provide a stable baseline, while assay-development opportunities are expanding into kidney-disease risk, metabolic dysfunction, obesity-related disease, endocrine disorders, and earlier identification of complications.

The future opportunity increasingly lies in combinations of biomarkers rather than single analytes. Tests capable of identifying which patients are progressing toward renal, cardiovascular, or metabolic complications could create significant clinical and payer value.

Cardiology

Cardiovascular assay development includes troponins, natriuretic peptides, lipids, coagulation markers, inflammatory biomarkers, genetic risk markers, and emerging multimarker approaches.

High-sensitivity cardiac assays are clinically valuable because diagnostic speed matters in emergency settings. Point-of-care platforms capable of delivering reliable cardiac results with short turnaround times remain an important development opportunity.

Neurology, Nephrology, Reproductive Health and Other Applications

Neurology is moving rapidly into the commercial IVD pipeline following advances in Alzheimer’s biomarkers and neurodegenerative disease research. Blood-based assays could significantly improve patient access compared with imaging or invasive specimen collection.

Nephrology creates demand for kidney-function and injury biomarkers, while reproductive health supports prenatal, fertility, sexually transmitted infection, pregnancy, and genetic testing. Autoimmune disease, transplantation, allergy, toxicology, and rare diseases provide additional specialized assay-development opportunities.

 

By End User

IVD and Diagnostic Manufacturers

IVD manufacturers represent the largest customer group because assay development is central to product pipeline expansion and installed-platform economics. Manufacturers with large analyzer bases continuously develop new assay menus because each additional clinically valuable test can increase recurring reagent revenue from existing instruments.

Large diagnostic manufacturers often maintain significant internal R&D capabilities but still use external development organizations for specialty antibodies, reference materials, validation, clinical studies, regulatory work, manufacturing transfer, and surge capacity.

Biotechnology and Pharmaceutical Companies

Pharmaceutical and biotechnology companies represent one of the highest-growth end-user groups. Precision therapies increasingly require biomarkers for clinical-trial enrollment, treatment selection, toxicity assessment, or response monitoring.

These companies may need assay support from early exploratory studies through commercialization. The most valuable development relationships therefore extend over several years and may progress from research-use biomarker testing to clinical trial assays and ultimately an FDA-authorized companion diagnostic.

Clinical and Reference Laboratories

Large reference laboratories and sophisticated health-system laboratories develop, validate, modify, and implement substantial numbers of tests. Their priorities include analytical reliability, throughput, automation compatibility, laboratory information-system integration, specimen logistics, and cost per reportable result.

The U.S. laboratory ecosystem provides significant scale, with hundreds of thousands of CLIA-regulated testing entities. Large laboratories also influence commercial assay design because manufacturers frequently optimize products around the workflow requirements of high-volume customers.

Academic Medical Centers and Research Institutions

Academic centers are important early-development partners because they combine specialized clinical expertise, biobanks, disease-specific patient populations, investigators, and access to translational research.

Novel biomarkers frequently enter clinical development through academic collaborations before moving into commercial diagnostic organizations. Cancer centers, neurological institutes, infectious-disease programs, and genomic medicine centers are particularly important.

Contract Research, Development and Manufacturing Organizations

Specialized CROs, assay-development companies, contract manufacturers, clinical research organizations, and regulatory consultancies are becoming increasingly important as diagnostic companies seek integrated outsourcing.

Customers increasingly prefer fewer handoffs between feasibility, validation, clinical evidence, quality, regulatory submission, and manufacturing. Providers capable of offering an integrated development pathway can therefore capture more revenue per program and create higher switching costs.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. IVD Assay Development Market is geographically segmented into the South, Northeast, West, and Midwest. Regional demand differs substantially according to biotechnology density, diagnostic manufacturing, pharmaceutical R&D, academic medical-center concentration, hospital laboratory capacity, venture investment, population size, disease burden, and availability of specialized molecular-testing infrastructure.

The South is estimated to represent the largest regional market in 2025, while the West is expected to record the fastest growth through 2035. The Northeast maintains the country’s highest concentration of pharmaceutical, biotechnology, academic, and translational-medicine programs, while the Midwest provides a strong combination of established diagnostics manufacturing, health-system laboratories, academic medicine, and cost-efficient development operations.

South

The South represented an estimated USD 0.55 billion in 2025 and is projected to approach approximately USD 1.35 billion by 2035, implying growth of roughly 9.4% annually.

The region comprises Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Delaware, West Virginia, Kentucky, Tennessee, Alabama, Mississippi, Arkansas, Louisiana and Oklahoma, with the District of Columbia forming an additional important federal research and policy center.

Texas is the largest development market in the South. Houston combines major medical institutions, cancer research, pathology expertise and translational medicine, while Austin and Dallas-Fort Worth have expanding biotechnology, molecular diagnostics, semiconductor, digital-health and life-science ecosystems. Texas also offers a large patient population for clinical validation.

North Carolina is particularly influential because the Research Triangle combines pharmaceutical companies, CROs, laboratory services, university research, biomanufacturing and regulatory expertise. The state’s infrastructure makes it especially attractive for outsourced assay development, companion diagnostics and clinical validation.

Maryland is another strategically important market because of the biotechnology corridor around Baltimore, Frederick and the Washington metropolitan area. Proximity to federal health agencies, major research institutions and biotechnology companies supports assay development in oncology, infectious disease and molecular diagnostics.

Virginia benefits from the broader Washington biotechnology ecosystem, large health systems and expanding genomic medicine capabilities. Georgia, led by Atlanta, combines major health systems, CDC-related public-health expertise, university research and an expanding life-science sector.

Florida represents a different opportunity. Its very large and aging population creates substantial demand for oncology, neurological, cardiac and chronic-disease testing. Miami, Tampa, Orlando and South Florida health systems are increasing their participation in clinical research and precision medicine.

Tennessee has important diagnostic and healthcare activity around Nashville and Memphis. Kentucky, South Carolina, Alabama, Louisiana, Oklahoma, Arkansas, Mississippi and West Virginia are smaller assay-development markets but contribute through academic laboratories, regional health systems, public-health testing and clinical-validation populations.

The South should remain the largest regional market because it combines high population growth with expanding biotechnology infrastructure and a relatively attractive cost base for laboratory operations. The region is also positioned to capture relocation and expansion by life-science companies seeking alternatives to higher-cost coastal markets.

West

The West represented approximately USD 0.47 billion in 2025 and is expected to reach about USD 1.25 billion by 2035, making it the fastest-growing U.S. region with an estimated CAGR of slightly above 10%.

The region includes California, Washington, Oregon, Arizona, Nevada, Utah, Colorado, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California dominates assay development in the West and is arguably the single most strategically important U.S. state for next-generation diagnostics. San Diego has one of the world’s leading genomics and sequencing clusters, while the San Francisco Bay Area combines biotechnology, oncology, digital health, AI, liquid biopsy and venture capital. Los Angeles and Orange County provide additional medical-device, diagnostics and clinical-research infrastructure.

California’s competitive advantage is particularly strong in oncology sequencing, liquid biopsy, companion diagnostics, AI-assisted diagnostics and decentralized molecular platforms. The state’s large population also facilitates diverse clinical-validation programs.

Washington has a sophisticated biotechnology and research ecosystem centered around Seattle. Genomics, immunology, cancer research and cloud computing create an attractive environment for diagnostics combining wet-laboratory assays with computational interpretation.

Utah has developed an influential molecular diagnostics and genetic-testing ecosystem around Salt Lake City. The state combines genetics expertise, entrepreneurial diagnostics companies and integrated healthcare data assets.

Colorado is growing around Denver, Boulder and Aurora, supported by academic medicine, biotechnology start-ups and research institutions. Arizona benefits from Phoenix’s population expansion, major health systems, precision-medicine activity and proximity to established California markets.

Oregon contributes university and biotechnology research, while Nevada is expanding health-science infrastructure around Las Vegas and Reno. New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii remain smaller commercial markets, although their geographic characteristics create demand for decentralized and point-of-care testing capable of reducing dependence on distant reference laboratories.

The West should gain national share through 2035 because the highest-growth categories—sequencing, liquid biopsy, computational diagnostics, AI-enabled assays, blood-based biomarkers and precision oncology—align closely with the region’s innovation ecosystem.

Northeast

The Northeast accounted for an estimated USD 0.52 billion in 2025 and is projected to approach approximately USD 1.08 billion by 2035.

The region includes Massachusetts, New York, Pennsylvania, New Jersey, Connecticut, Rhode Island, New Hampshire, Vermont and Maine.

Massachusetts is the region’s premier development market. Greater Boston and Cambridge have extraordinary concentrations of biotechnology companies, pharmaceutical R&D, academic hospitals, genomics laboratories and venture-backed diagnostic start-ups. Assay development demand is particularly strong in oncology, rare disease, immunology, companion diagnostics, gene therapy and precision medicine.

New Jersey remains strategically important because of its pharmaceutical manufacturing and corporate R&D base. Assay development frequently intersects with drug-development programs, making the state’s biopharmaceutical concentration especially relevant.

New York combines a large healthcare market with leading cancer centers, academic institutions, pathology laboratories and biotechnology companies. New York City is influential in oncology and genomic medicine, while the state also maintains significant clinical laboratory infrastructure.

Pennsylvania provides important clusters around Philadelphia and Pittsburgh. Philadelphia’s cell and gene therapy, pharmaceutical and academic research ecosystem creates growing biomarker and companion diagnostic opportunities, while Pittsburgh contributes precision medicine, digital pathology and health-system innovation.

Connecticut benefits from proximity to the Boston-New York corridor and established pharmaceutical and research organizations. Rhode Island, New Hampshire, Vermont and Maine are smaller markets but contribute academic research, specialized laboratories and clinical-validation capacity.

The Northeast is expected to grow more slowly than the West because its assay-development ecosystem is already highly mature. Nevertheless, it should maintain premium value per project because complex pharmaceutical-linked and oncology diagnostic programs are concentrated in the region.

Midwest

The Midwest represented approximately USD 0.30 billion in 2025 and is expected to reach roughly USD 0.72 billion by 2035.

The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota and South Dakota.

Minnesota is a particularly important diagnostics and medical-device market because of its established medtech ecosystem, specialist manufacturers, health systems and clinical expertise. The state’s experience translating healthcare technology into regulated products provides a strong foundation for assay commercialization.

Illinois is led by the Chicago metropolitan market, which combines large academic hospitals, diagnostics companies, reference laboratories, biotechnology research and a large patient base.

Ohio has significant clinical and research capabilities around Cleveland, Columbus and Cincinnati. Major academic health systems support oncology, transplantation, cardiovascular and molecular diagnostic research.

Michigan contributes university research, health-system laboratories and life-science capabilities centered around Ann Arbor and Detroit. Wisconsin benefits from strong academic medicine and diagnostics activity around Madison.

Indiana has extensive pharmaceutical and life-science infrastructure, particularly around Indianapolis. Missouri contributes through St. Louis biotechnology and medical research, while Iowa, Kansas and Nebraska provide academic and agricultural-biotechnology capabilities that can support laboratory technology development.

North Dakota and South Dakota represent smaller markets but have relevance for regional laboratory networks and decentralized diagnostics because rural populations benefit disproportionately from technologies that reduce sample transportation and specialist-laboratory dependency.

The Midwest’s competitive advantage is likely to be cost-effective assay development, manufacturing transfer, clinical validation and health-system collaboration rather than the venture-driven innovation concentration seen in California or Massachusetts.

 

Key Market Players

The U.S. IVD Assay Development Competitive Landscape is fragmented across several distinct competitor groups. These include specialist assay-development organizations, large diagnostics manufacturers, reagent and reference-material suppliers, contract research providers, sequencing companies, clinical laboratories, and integrated life-science technology companies.

Competition is increasingly based on the ability to control more of the development pathway. Customers prefer organizations that can move from biomarker concept to feasibility, analytical optimization, validation, clinical studies, design transfer, regulatory submission and commercialization without requiring repeated technology transfers between suppliers.

Some of the key players participating in or influencing the U.S. IVD Assay Development ecosystem include:

• Thermo Fisher Scientific
• Danaher Corporation
• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Becton, Dickinson and Company
• bioMérieux
• QuidelOrtho Corporation
• Bio-Rad Laboratories
• QIAGEN
• Hologic
• Illumina
• Agilent Technologies
• Bio-Techne Corporation
• Revvity
• Promega Corporation
• Meridian Bioscience
• LGC Clinical Diagnostics / SeraCare
• Fujirebio Diagnostics
• Maxim Biomedical
• Avioq
• Creative Biolabs
• ICON plc
• Labcorp
• Quest Diagnostics

Thermo Fisher Scientific has one of the broadest positions in the development ecosystem through molecular biology, antibodies, reagents, sequencing, clinical research, diagnostic platforms and contract capabilities. Danaher participates through operating companies spanning molecular diagnostics, laboratory automation, life-science research tools and clinical instrumentation.

Roche, Abbott, Siemens Healthineers, BD, bioMérieux, QuidelOrtho and Hologic are major commercial IVD companies whose assay pipelines help define development standards across centralized and decentralized testing.

QIAGEN, Illumina and Agilent are particularly important in molecular and genomic diagnostics. Their technologies influence sample preparation, amplification, sequencing, bioinformatics and companion diagnostic development.

Bio-Techne, Bio-Rad, Promega, Meridian Bioscience, Revvity and LGC Clinical Diagnostics contribute critical antibodies, proteins, controls, reference materials, enzymes, assay technologies and development infrastructure.

Specialist providers such as Maxim Biomedical, Avioq and Creative Biolabs compete through custom assay expertise and flexible development services.

ICON, Labcorp and Quest Diagnostics influence the market through clinical research, central laboratory testing, biomarker programs, validation capabilities and access to extensive clinical-testing infrastructure.

The competitive balance through 2035 will be shaped by scientific specialization, development speed, quality systems, clinical-site access, FDA experience, automation expertise, supply-chain security, and the ability to transition a successful prototype into scalable manufacturing.

 

Recent Developments

Recent developments in the U.S. IVD Assay Development Market demonstrate that the industry is moving toward higher-complexity assays with greater direct influence on clinical decisions.

In May 2025, the FDA cleared the first blood-based IVD intended to aid diagnosis of Alzheimer’s disease. The test measures the relationship between pTau217 and beta-amyloid 1-42 in plasma and provides a less invasive alternative to testing approaches that rely on cerebrospinal fluid or imaging. The clearance substantially strengthens commercial interest in neurological blood biomarkers and should stimulate development of additional neurodegenerative-disease assays.

In July 2024, the FDA approved Guardant Health’s Shield blood test for colorectal cancer screening in average-risk individuals aged 45 years and older. The test analyzes cell-free DNA characteristics including genomic and epigenomic information. Its approval demonstrates that sophisticated multi-signal liquid-biopsy technologies can transition from advanced laboratory development into population-scale cancer screening applications.

In August 2024, the FDA approved Illumina’s TruSight Oncology Comprehensive, a targeted NGS IVD capable of analyzing more than 500 genes in solid tumors. The approval illustrates the increasing complexity of commercial oncology assays and the importance of integrated DNA, RNA, sequencing and bioinformatics validation.

In July 2025, FDA approval of the Oncomine Dx Express Test further advanced integrated oncology sequencing. The assay detects multiple classes of genomic alterations using an automated sequencing platform and supports both tumor profiling and companion diagnostic use. Developments of this type are shifting molecular testing toward faster, more standardized workflows that can be deployed beyond the largest reference laboratories.

FDA companion diagnostic activity also continued to expand during 2025 and 2026. New biomarker-treatment combinations and label expansions are increasing the number of therapeutic decisions that depend on a validated diagnostic result. This strengthens demand for drug-diagnostic codevelopment, bridging studies, assay transfer and lifecycle regulatory support.

The U.S. regulatory landscape experienced an important change in March 2025, when a federal district court vacated the FDA’s 2024 final rule concerning laboratory-developed tests. FDA later restored the applicable regulatory text to its earlier form. The episode increased industry attention to regulatory scenario planning and reinforced the value of development strategies capable of adapting to changing oversight requirements.

Multiplex infectious-disease testing is also becoming more prominent. By 2026, clinical guidance continued to recognize multiplex nucleic-acid assays capable of differentiating influenza, SARS-CoV-2 and other respiratory pathogens. This supports continued investment in cartridge-based molecular assays, home testing, rapid syndromic diagnostics and flexible platform menus.

The larger strategic direction is clear: successful IVD programs increasingly combine assay chemistry, software, clinical evidence, regulatory strategy and workflow engineering. Development organizations that remain focused only on wet-laboratory optimization risk losing share to integrated providers capable of supporting commercialization.

 

Conclusion

The U.S. IVD Assay Development Market Size & Share is positioned for sustained expansion from approximately USD 1.84 billion in 2025 to USD 4.40 billion by 2035, reflecting a 9.10% CAGR during 2026–2035.

The long-term growth thesis is supported by the scale of U.S. clinical laboratory testing, continued expansion of precision medicine, oncology biomarker development, molecular diagnostics, companion diagnostics, decentralized testing, chronic-disease screening, antimicrobial-resistance testing, and emerging blood-based biomarkers.

The highest-value opportunity is shifting toward clinically consequential assays. Oncology sequencing, liquid biopsy, Alzheimer’s blood biomarkers, companion diagnostics, molecular infectious-disease panels, antimicrobial-resistance assays and multi-marker risk algorithms require substantially more development expertise than conventional single-analyte tests. These programs consequently generate larger addressable revenue per development project.

From a technology perspective, molecular diagnostics should deliver the fastest expansion, while immunoassay remains the largest and most commercially established development category. Infectious disease will remain a core application, but oncology is expected to gain the most strategic value through 2035 because assay results are becoming directly linked to treatment selection and precision therapeutic pathways.

The regional opportunity is led by the South’s combination of population scale, Research Triangle activity, Texas medical infrastructure and expanding biotechnology investment. The West should grow fastest because California, Washington and Utah have strong positions in sequencing, liquid biopsy, genomics and computational diagnostics. The Northeast will remain the premium pharmaceutical and translational-research region, while the Midwest should retain a durable position in diagnostics manufacturing, clinical validation and cost-efficient development.

For report buyers, the most important question is not simply how quickly assay-development spending will grow. The strategic issue is where clinical complexity is creating the largest development budgets, which diagnostic technologies are likely to achieve scalable clinical adoption, which development capabilities will remain scarce, and how regulatory, reimbursement and laboratory workflow requirements will shape commercialization economics.

Companies that combine strong assay science with regulatory planning, clinical-validation capability, manufacturability, automation expertise, reference-material quality, and commercial workflow understanding will capture the highest-value opportunities in the U.S. IVD assay development market through 2035.

 

TABLE OF CONTENT

1. U.S. IVD Assay Development Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. IVD and Diagnostic Manufacturers
1.6.2. Assay Development and Contract Research Organizations
1.6.3. Pharmaceutical and Biotechnology Companies
1.6.4. Clinical and Reference Laboratories
1.6.5. Academic Medical Centers and Research Institutions
1.6.6. Reagent, Antibody, Enzyme and Reference Material Suppliers
1.6.7. Contract Manufacturing and Design Transfer Partners
1.6.8. Healthcare Providers and Health Systems
1.6.9. Payers, Regulators and Clinical Decision-Makers

What this section provides: This section defines the U.S. IVD assay development market boundary, research scope, market-sizing methodology, assumptions and stakeholder ecosystem, helping clients understand how assay development revenues and commercialization opportunities are measured and validated.

2. U.S. IVD Assay Development Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size Opportunity, 2025–2035
2.8. High-Growth Opportunity Areas
2.8.1. Molecular Diagnostic Assay Development
2.8.2. Oncology and Companion Diagnostics
2.8.3. Liquid Biopsy Assays
2.8.4. Multiplex Infectious Disease Testing
2.8.5. Neurological Blood-Based Biomarkers
2.8.6. Point-of-Care and Decentralized Testing

What this section provides: This section gives decision-makers a concise view of market size, growth trajectory, high-value technology areas, customer demand, competitive intensity and priority opportunities through 2035.

3. U.S. IVD Assay Development Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Clinical Laboratory Testing Volumes in the U.S.
3.1.2. Growth in Molecular and Genomic Diagnostics
3.1.3. Expansion of Precision Medicine and Companion Diagnostics
3.1.4. Growing Oncology Biomarker Development
3.1.5. Rising Demand for Multiplex Infectious Disease Assays
3.1.6. Expansion of Point-of-Care and Decentralized Diagnostics
3.1.7. Growth in Pharmaceutical Biomarker and Clinical Trial Programs
3.1.8. Increasing Demand for Outsourced Assay Development
3.1.9. Growing Adoption of Blood-Based Diagnostic Biomarkers
3.2. Restraints and Their Impact Analysis
3.2.1. High Assay Development and Clinical Validation Costs
3.2.2. Complex FDA Regulatory Requirements
3.2.3. Biomarker Translation and Clinical Utility Risk
3.2.4. Reimbursement Uncertainty for Novel Diagnostic Tests
3.2.5. Shortage of Specialized Molecular and Bioinformatics Expertise
3.2.6. Reagent and Reference Material Supply Constraints
3.3. Opportunities and Their Impact Analysis
3.3.1. Liquid Biopsy and Cell-Free DNA Assay Development
3.3.2. Companion Diagnostic Co-Development
3.3.3. Alzheimer’s and Neurological Biomarker Assays
3.3.4. Antimicrobial Resistance Diagnostics
3.3.5. Multi-Cancer and Early Detection Assays
3.3.6. AI-Enabled Multi-Analyte Diagnostic Algorithms
3.3.7. Home and Near-Patient Molecular Testing
3.3.8. Laboratory Automation and High-Throughput Testing
3.4. Challenges and Their Impact Analysis
3.4.1. Analytical Reproducibility Across Testing Sites
3.4.2. Clinical Sample Access and Recruitment
3.4.3. Assay Scale-Up and Design Transfer Complexity
3.4.4. Bioinformatics Validation Requirements
3.4.5. Laboratory Workflow Integration
3.4.6. Commercialization Risk for Novel Biomarkers
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Diagnostic Laboratory Workflow Economics Analysis
3.7. Assay Development Cost Structure Analysis
3.8. Outsourcing vs. In-House Assay Development Analysis
3.9. Biomarker-to-Commercial Assay Conversion Analysis

What this section provides: This section explains the scientific, clinical, regulatory, commercial and operational forces determining U.S. IVD assay development demand and helps clients evaluate market upside, commercialization risk and development bottlenecks.

4. U.S. IVD Assay Development Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Assay Development Pricing Trend Analysis, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Biomarker Discovery-to-Commercialization Value Chain
4.6. Application & Innovation Landscape
4.7. FDA IVD Regulatory Framework Analysis
4.7.1. 510(k) Pathway
4.7.2. De Novo Classification Pathway
4.7.3. Premarket Approval Pathway
4.7.4. Companion Diagnostic Regulatory Considerations
4.7.5. Investigational Use and Clinical Study Considerations
4.8. CLIA and Laboratory Testing Framework
4.9. CMS Reimbursement and Coverage Landscape
4.10. CPT, PLA and Diagnostic Coding Considerations
4.11. Quality System and Design Control Requirements
4.12. Reference Materials and Analytical Standards Landscape
4.13. Impact of Digitalization and Laboratory Automation
4.14. Impact of AI and Bioinformatics on IVD Assay Development
4.15. Import/Export Restrictions & Tariff Impact
4.16. Government Initiatives and Public Health Programs
4.17. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.18. Diagnostic Commercialization Decision Framework

What this section provides: This section gives clients a comprehensive view of regulatory pathways, reimbursement, laboratory standards, assay pricing, technological change, quality requirements, supply-chain exposure and commercialization conditions affecting the U.S. market.

5. U.S. IVD Assay Development Market – By Offering

5.1. Overview
5.1.1. Segment Share Analysis, By Offering, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Offering, 2021–2035 (US$ Billion)
5.2. IVD Assay Development Services
5.2.1. Assay Feasibility Assessment
5.2.2. Biomarker and Target Selection
5.2.3. Reagent and Antibody Screening
5.2.4. Primer and Probe Design
5.2.5. Assay Optimization
5.2.6. Prototype Development
5.2.7. Analytical Verification
5.3. IVD Assay Stability Testing
5.3.1. Real-Time Stability Testing
5.3.2. Accelerated Stability Testing
5.3.3. Freeze-Thaw Stability
5.3.4. Open-Vial and Onboard Stability
5.3.5. Shipping and Environmental Stress Testing
5.4. Packaging and Design Transfer Services
5.4.1. Kit and Reagent Packaging Development
5.4.2. Design Transfer
5.4.3. Manufacturing Scale-Up Support
5.4.4. Process Documentation
5.5. Regulatory, Validation and Quality Support
5.5.1. Analytical Validation
5.5.2. Clinical Validation
5.5.3. Regulatory Strategy
5.5.4. FDA Submission Support
5.5.5. Quality Management Documentation
5.5.6. Biostatistics and Data Analysis
5.6. Technology Transfer and Custom QA/QC Services
5.6.1. Method Transfer
5.6.2. Reference Material Development
5.6.3. Quality Control Development
5.6.4. Lot-to-Lot Verification
5.6.5. Post-Development Technical Support

What this section provides: This section identifies which IVD assay development services generate the highest revenue contribution and where customers are increasing spending across feasibility, validation, stability, regulatory support, design transfer and quality control.

6. U.S. IVD Assay Development Market – By Technology

6.1. Overview
6.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
6.2. Immunoassay and Immunochemistry
6.2.1. Enzyme-Linked Immunosorbent Assays
6.2.2. Chemiluminescent Immunoassays
6.2.3. Fluorescence Immunoassays
6.2.4. Lateral Flow Immunoassays
6.2.5. Multiplex Immunoassays
6.3. Molecular Diagnostics
6.3.1. Polymerase Chain Reaction
6.3.2. Real-Time PCR
6.3.3. Digital PCR
6.3.4. Multiplex PCR
6.3.5. Isothermal Nucleic Acid Amplification
6.3.6. Next-Generation Sequencing
6.3.7. Genotyping and Mutation Detection
6.3.8. Liquid Biopsy and Cell-Free Nucleic Acid Assays
6.4. Clinical Chemistry and Biochemistry
6.4.1. Metabolite Assays
6.4.2. Enzyme Assays
6.4.3. Protein and Electrolyte Assays
6.4.4. Specialized Chemistry Assays
6.5. Hematology and Coagulation
6.5.1. Hematology Assays
6.5.2. Coagulation Assays
6.5.3. Platelet Function Assays
6.5.4. Hemoglobin Analysis
6.6. Microbiology and Urinalysis
6.6.1. Microbiology Assays
6.6.2. Antimicrobial Resistance Assays
6.6.3. Rapid Pathogen Identification
6.6.4. Urinalysis Assays
6.6.5. Automated Microscopy and Digital Analysis

What this section provides: This section evaluates the assay technologies shaping market growth and highlights the transition toward molecular diagnostics, sequencing, multiplexing, high-sensitivity immunoassays and automated diagnostic workflows.

7. U.S. IVD Assay Development Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
7.2. Infectious Diseases
7.2.1. Respiratory Infections
7.2.2. Sexually Transmitted Infections
7.2.3. Gastrointestinal Infections
7.2.4. Bloodstream Infections
7.2.5. Hepatitis and HIV
7.2.6. Antimicrobial Resistance
7.2.7. Healthcare-Associated Infections
7.3. Oncology
7.3.1. Cancer Screening
7.3.2. Tumor Profiling
7.3.3. Companion Diagnostics
7.3.4. Liquid Biopsy
7.3.5. Minimal Residual Disease
7.3.6. Treatment Response Monitoring
7.3.7. Multi-Cancer Early Detection
7.4. Diabetes and Metabolic Diseases
7.4.1. Diabetes Diagnosis and Monitoring
7.4.2. Renal Complication Biomarkers
7.4.3. Metabolic Dysfunction
7.4.4. Endocrine Disorders
7.5. Cardiology
7.5.1. Cardiac Biomarkers
7.5.2. Lipid and Cardiovascular Risk Testing
7.5.3. Coagulation and Thrombosis
7.5.4. Genetic Cardiovascular Testing
7.6. Neurology, Nephrology, Reproductive Health and Other Applications
7.6.1. Alzheimer’s Disease and Neurodegenerative Disorders
7.6.2. Renal Disease
7.6.3. Prenatal and Reproductive Health
7.6.4. Autoimmune Diseases
7.6.5. Transplantation
7.6.6. Rare and Genetic Diseases
7.6.7. Allergy and Toxicology

What this section provides: This section helps clients identify clinical applications generating the strongest assay-development demand, with particular focus on infectious disease, oncology, companion diagnostics, metabolic disease and emerging neurological biomarkers.

8. U.S. IVD Assay Development Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
8.2. IVD and Diagnostic Manufacturers
8.2.1. Large Integrated IVD Companies
8.2.2. Molecular Diagnostic Companies
8.2.3. Point-of-Care Diagnostic Manufacturers
8.2.4. Emerging Diagnostic Startups
8.3. Biotechnology and Pharmaceutical Companies
8.3.1. Pharmaceutical Companies
8.3.2. Biotechnology Companies
8.3.3. Precision Medicine Developers
8.3.4. Companion Diagnostic Sponsors
8.4. Clinical and Reference Laboratories
8.4.1. National Reference Laboratories
8.4.2. Hospital Laboratories
8.4.3. Independent Clinical Laboratories
8.4.4. Molecular and Genomic Laboratories
8.5. Academic Medical Centers and Research Institutions
8.5.1. Academic Medical Centers
8.5.2. Cancer Research Centers
8.5.3. University Laboratories
8.5.4. Government and Public Health Laboratories
8.6. Contract Research, Development and Manufacturing Organizations
8.6.1. Assay Development CROs
8.6.2. Clinical Research Organizations
8.6.3. Contract Manufacturing Organizations
8.6.4. Regulatory and Validation Service Providers

What this section provides: This section identifies the customer groups driving U.S. assay-development spending and evaluates outsourcing behavior, pipeline requirements, commercialization needs and purchasing priorities across diagnostic, pharmaceutical and laboratory organizations.

9. U.S. IVD Assay Development Market: Development & Commercialization Pathway Analysis

9.1. Biomarker Discovery and Target Selection
9.2. Assay Feasibility and Proof-of-Concept
9.3. Prototype Assay Development
9.4. Analytical Optimization
9.5. Analytical Verification
9.6. Analytical Validation
9.6.1. Accuracy
9.6.2. Precision
9.6.3. Analytical Sensitivity
9.6.4. Analytical Specificity
9.6.5. Limit of Detection
9.6.6. Linearity and Measuring Range
9.6.7. Interference and Cross-Reactivity
9.6.8. Reproducibility
9.7. Clinical Validation and Performance Studies
9.8. Design Transfer and Manufacturing Scale-Up
9.9. Regulatory Submission Strategy
9.10. Laboratory Workflow Integration
9.11. Reimbursement and Market Access Planning
9.12. Commercial Launch Readiness
9.13. Post-Market Assay Lifecycle Management
9.14. Typical Development Timeline Analysis
9.15. Development Cost and Outsourcing Economics

What this section provides: This section maps the complete biomarker-to-commercial-assay pathway and helps clients identify development costs, technical milestones, regulatory dependencies, outsourcing opportunities and commercialization risk.

10. U.S. IVD Assay Development Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diagnostic and Biotechnology Ecosystem Analysis
10.1.4. Regional Clinical Laboratory Infrastructure Analysis
10.1.5. Regional Pharmaceutical and Companion Diagnostic Activity
10.1.6. Regional Assay Development Outsourcing Dynamics
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region IVD Assay Development Companies and Research Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Offering, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. California
10.2.8.1. Overview
10.2.8.2. California Market Size and Forecast, By Offering, 2021–2035
10.2.8.3. California Market Size and Forecast, By Technology, 2021–2035
10.2.8.4. California Market Size and Forecast, By Application, 2021–2035
10.2.8.5. California Market Size and Forecast, By End User, 2021–2035
10.2.9. Washington
10.2.9.1. Overview
10.2.9.2. Washington Market Size and Forecast, By Offering, 2021–2035
10.2.9.3. Washington Market Size and Forecast, By Technology, 2021–2035
10.2.9.4. Washington Market Size and Forecast, By Application, 2021–2035
10.2.9.5. Washington Market Size and Forecast, By End User, 2021–2035
10.2.10. Arizona
10.2.10.1. Overview
10.2.10.2. Arizona Market Size and Forecast, By Offering, 2021–2035
10.2.10.3. Arizona Market Size and Forecast, By Technology, 2021–2035
10.2.10.4. Arizona Market Size and Forecast, By Application, 2021–2035
10.2.10.5. Arizona Market Size and Forecast, By End User, 2021–2035
10.2.11. Colorado
10.2.11.1. Overview
10.2.11.2. Colorado Market Size and Forecast, By Offering, 2021–2035
10.2.11.3. Colorado Market Size and Forecast, By Technology, 2021–2035
10.2.11.4. Colorado Market Size and Forecast, By Application, 2021–2035
10.2.11.5. Colorado Market Size and Forecast, By End User, 2021–2035
10.2.12. Oregon
10.2.12.1. Overview
10.2.12.2. Oregon Market Size and Forecast, By Offering, 2021–2035
10.2.12.3. Oregon Market Size and Forecast, By Technology, 2021–2035
10.2.12.4. Oregon Market Size and Forecast, By Application, 2021–2035
10.2.12.5. Oregon Market Size and Forecast, By End User, 2021–2035
10.2.13. Utah
10.2.13.1. Overview
10.2.13.2. Utah Market Size and Forecast, By Offering, 2021–2035
10.2.13.3. Utah Market Size and Forecast, By Technology, 2021–2035
10.2.13.4. Utah Market Size and Forecast, By Application, 2021–2035
10.2.13.5. Utah Market Size and Forecast, By End User, 2021–2035
10.2.14. Nevada
10.2.14.1. Overview
10.2.14.2. Nevada Market Size and Forecast, By Offering, 2021–2035
10.2.14.3. Nevada Market Size and Forecast, By Technology, 2021–2035
10.2.14.4. Nevada Market Size and Forecast, By Application, 2021–2035
10.2.14.5. Nevada Market Size and Forecast, By End User, 2021–2035
10.2.15. New Mexico
10.2.15.1. Overview
10.2.15.2. New Mexico Market Size and Forecast, By Offering, 2021–2035
10.2.15.3. New Mexico Market Size and Forecast, By Technology, 2021–2035
10.2.15.4. New Mexico Market Size and Forecast, By Application, 2021–2035
10.2.15.5. New Mexico Market Size and Forecast, By End User, 2021–2035
10.2.16. Idaho
10.2.16.1. Overview
10.2.16.2. Idaho Market Size and Forecast, By Offering, 2021–2035
10.2.16.3. Idaho Market Size and Forecast, By Technology, 2021–2035
10.2.16.4. Idaho Market Size and Forecast, By Application, 2021–2035
10.2.16.5. Idaho Market Size and Forecast, By End User, 2021–2035
10.2.17. Montana
10.2.17.1. Overview
10.2.17.2. Montana Market Size and Forecast, By Offering, 2021–2035
10.2.17.3. Montana Market Size and Forecast, By Technology, 2021–2035
10.2.17.4. Montana Market Size and Forecast, By Application, 2021–2035
10.2.17.5. Montana Market Size and Forecast, By End User, 2021–2035
10.2.18. Wyoming
10.2.18.1. Overview
10.2.18.2. Wyoming Market Size and Forecast, By Offering, 2021–2035
10.2.18.3. Wyoming Market Size and Forecast, By Technology, 2021–2035
10.2.18.4. Wyoming Market Size and Forecast, By Application, 2021–2035
10.2.18.5. Wyoming Market Size and Forecast, By End User, 2021–2035
10.2.19. Alaska
10.2.19.1. Overview
10.2.19.2. Alaska Market Size and Forecast, By Offering, 2021–2035
10.2.19.3. Alaska Market Size and Forecast, By Technology, 2021–2035
10.2.19.4. Alaska Market Size and Forecast, By Application, 2021–2035
10.2.19.5. Alaska Market Size and Forecast, By End User, 2021–2035
10.2.20. Hawaii
10.2.20.1. Overview
10.2.20.2. Hawaii Market Size and Forecast, By Offering, 2021–2035
10.2.20.3. Hawaii Market Size and Forecast, By Technology, 2021–2035
10.2.20.4. Hawaii Market Size and Forecast, By Application, 2021–2035
10.2.20.5. Hawaii Market Size and Forecast, By End User, 2021–2035
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast IVD Assay Development Companies and Research Ecosystem
10.3.3. Northeast Market Size and Forecast, By State, 2021–2035
10.3.4. Northeast Market Size and Forecast, By Offering, 2021–2035
10.3.5. Northeast Market Size and Forecast, By Technology, 2021–2035
10.3.6. Northeast Market Size and Forecast, By Application, 2021–2035
10.3.7. Northeast Market Size and Forecast, By End User, 2021–2035
10.3.8. New York
10.3.8.1. Overview
10.3.8.2. New York Market Size and Forecast, By Offering, 2021–2035
10.3.8.3. New York Market Size and Forecast, By Technology, 2021–2035
10.3.8.4. New York Market Size and Forecast, By Application, 2021–2035
10.3.8.5. New York Market Size and Forecast, By End User, 2021–2035
10.3.9. Massachusetts
10.3.9.1. Overview
10.3.9.2. Massachusetts Market Size and Forecast, By Offering, 2021–2035
10.3.9.3. Massachusetts Market Size and Forecast, By Technology, 2021–2035
10.3.9.4. Massachusetts Market Size and Forecast, By Application, 2021–2035
10.3.9.5. Massachusetts Market Size and Forecast, By End User, 2021–2035
10.3.10. New Jersey
10.3.10.1. Overview
10.3.10.2. New Jersey Market Size and Forecast, By Offering, 2021–2035
10.3.10.3. New Jersey Market Size and Forecast, By Technology, 2021–2035
10.3.10.4. New Jersey Market Size and Forecast, By Application, 2021–2035
10.3.10.5. New Jersey Market Size and Forecast, By End User, 2021–2035
10.3.11. Pennsylvania
10.3.11.1. Overview
10.3.11.2. Pennsylvania Market Size and Forecast, By Offering, 2021–2035
10.3.11.3. Pennsylvania Market Size and Forecast, By Technology, 2021–2035
10.3.11.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035
10.3.11.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035
10.3.12. Connecticut
10.3.12.1. Overview
10.3.12.2. Connecticut Market Size and Forecast, By Offering, 2021–2035
10.3.12.3. Connecticut Market Size and Forecast, By Technology, 2021–2035
10.3.12.4. Connecticut Market Size and Forecast, By Application, 2021–2035
10.3.12.5. Connecticut Market Size and Forecast, By End User, 2021–2035
10.3.13. Maine
10.3.13.1. Overview
10.3.13.2. Maine Market Size and Forecast, By Offering, 2021–2035
10.3.13.3. Maine Market Size and Forecast, By Technology, 2021–2035
10.3.13.4. Maine Market Size and Forecast, By Application, 2021–2035
10.3.13.5. Maine Market Size and Forecast, By End User, 2021–2035
10.3.14. Vermont
10.3.14.1. Overview
10.3.14.2. Vermont Market Size and Forecast, By Offering, 2021–2035
10.3.14.3. Vermont Market Size and Forecast, By Technology, 2021–2035
10.3.14.4. Vermont Market Size and Forecast, By Application, 2021–2035
10.3.14.5. Vermont Market Size and Forecast, By End User, 2021–2035
10.3.15. New Hampshire
10.3.15.1. Overview
10.3.15.2. New Hampshire Market Size and Forecast, By Offering, 2021–2035
10.3.15.3. New Hampshire Market Size and Forecast, By Technology, 2021–2035
10.3.15.4. New Hampshire Market Size and Forecast, By Application, 2021–2035
10.3.15.5. New Hampshire Market Size and Forecast, By End User, 2021–2035
10.3.16. Rhode Island
10.3.16.1. Overview
10.3.16.2. Rhode Island Market Size and Forecast, By Offering, 2021–2035
10.3.16.3. Rhode Island Market Size and Forecast, By Technology, 2021–2035
10.3.16.4. Rhode Island Market Size and Forecast, By Application, 2021–2035
10.3.16.5. Rhode Island Market Size and Forecast, By End User, 2021–2035
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region IVD Assay Development Companies and Research Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035
10.4.4. South Region Market Size and Forecast, By Offering, 2021–2035
10.4.5. South Region Market Size and Forecast, By Technology, 2021–2035
10.4.6. South Region Market Size and Forecast, By Application, 2021–2035
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035
10.4.8. Texas
10.4.8.1. Overview
10.4.8.2. Texas Market Size and Forecast, By Offering, 2021–2035
10.4.8.3. Texas Market Size and Forecast, By Technology, 2021–2035
10.4.8.4. Texas Market Size and Forecast, By Application, 2021–2035
10.4.8.5. Texas Market Size and Forecast, By End User, 2021–2035
10.4.9. Florida
10.4.9.1. Overview
10.4.9.2. Florida Market Size and Forecast, By Offering, 2021–2035
10.4.9.3. Florida Market Size and Forecast, By Technology, 2021–2035
10.4.9.4. Florida Market Size and Forecast, By Application, 2021–2035
10.4.9.5. Florida Market Size and Forecast, By End User, 2021–2035
10.4.10. Georgia
10.4.10.1. Overview
10.4.10.2. Georgia Market Size and Forecast, By Offering, 2021–2035
10.4.10.3. Georgia Market Size and Forecast, By Technology, 2021–2035
10.4.10.4. Georgia Market Size and Forecast, By Application, 2021–2035
10.4.10.5. Georgia Market Size and Forecast, By End User, 2021–2035
10.4.11. North Carolina
10.4.11.1. Overview
10.4.11.2. North Carolina Market Size and Forecast, By Offering, 2021–2035
10.4.11.3. North Carolina Market Size and Forecast, By Technology, 2021–2035
10.4.11.4. North Carolina Market Size and Forecast, By Application, 2021–2035
10.4.11.5. North Carolina Market Size and Forecast, By End User, 2021–2035
10.4.12. Tennessee
10.4.12.1. Overview
10.4.12.2. Tennessee Market Size and Forecast, By Offering, 2021–2035
10.4.12.3. Tennessee Market Size and Forecast, By Technology, 2021–2035
10.4.12.4. Tennessee Market Size and Forecast, By Application, 2021–2035
10.4.12.5. Tennessee Market Size and Forecast, By End User, 2021–2035
10.4.13. South Carolina
10.4.13.1. Overview
10.4.13.2. South Carolina Market Size and Forecast, By Offering, 2021–2035
10.4.13.3. South Carolina Market Size and Forecast, By Technology, 2021–2035
10.4.13.4. South Carolina Market Size and Forecast, By Application, 2021–2035
10.4.13.5. South Carolina Market Size and Forecast, By End User, 2021–2035
10.4.14. Alabama
10.4.14.1. Overview
10.4.14.2. Alabama Market Size and Forecast, By Offering, 2021–2035
10.4.14.3. Alabama Market Size and Forecast, By Technology, 2021–2035
10.4.14.4. Alabama Market Size and Forecast, By Application, 2021–2035
10.4.14.5. Alabama Market Size and Forecast, By End User, 2021–2035
10.4.15. Mississippi
10.4.15.1. Overview
10.4.15.2. Mississippi Market Size and Forecast, By Offering, 2021–2035
10.4.15.3. Mississippi Market Size and Forecast, By Technology, 2021–2035
10.4.15.4. Mississippi Market Size and Forecast, By Application, 2021–2035
10.4.15.5. Mississippi Market Size and Forecast, By End User, 2021–2035
10.4.16. Louisiana
10.4.16.1. Overview
10.4.16.2. Louisiana Market Size and Forecast, By Offering, 2021–2035
10.4.16.3. Louisiana Market Size and Forecast, By Technology, 2021–2035
10.4.16.4. Louisiana Market Size and Forecast, By Application, 2021–2035
10.4.16.5. Louisiana Market Size and Forecast, By End User, 2021–2035
10.4.17. Arkansas
10.4.17.1. Overview
10.4.17.2. Arkansas Market Size and Forecast, By Offering, 2021–2035
10.4.17.3. Arkansas Market Size and Forecast, By Technology, 2021–2035
10.4.17.4. Arkansas Market Size and Forecast, By Application, 2021–2035
10.4.17.5. Arkansas Market Size and Forecast, By End User, 2021–2035
10.4.18. Kentucky
10.4.18.1. Overview
10.4.18.2. Kentucky Market Size and Forecast, By Offering, 2021–2035
10.4.18.3. Kentucky Market Size and Forecast, By Technology, 2021–2035
10.4.18.4. Kentucky Market Size and Forecast, By Application, 2021–2035
10.4.18.5. Kentucky Market Size and Forecast, By End User, 2021–2035
10.4.19. Oklahoma
10.4.19.1. Overview
10.4.19.2. Oklahoma Market Size and Forecast, By Offering, 2021–2035
10.4.19.3. Oklahoma Market Size and Forecast, By Technology, 2021–2035
10.4.19.4. Oklahoma Market Size and Forecast, By Application, 2021–2035
10.4.19.5. Oklahoma Market Size and Forecast, By End User, 2021–2035
10.4.20. Virginia
10.4.20.1. Overview
10.4.20.2. Virginia Market Size and Forecast, By Offering, 2021–2035
10.4.20.3. Virginia Market Size and Forecast, By Technology, 2021–2035
10.4.20.4. Virginia Market Size and Forecast, By Application, 2021–2035
10.4.20.5. Virginia Market Size and Forecast, By End User, 2021–2035
10.4.21. Maryland
10.4.21.1. Overview
10.4.21.2. Maryland Market Size and Forecast, By Offering, 2021–2035
10.4.21.3. Maryland Market Size and Forecast, By Technology, 2021–2035
10.4.21.4. Maryland Market Size and Forecast, By Application, 2021–2035
10.4.21.5. Maryland Market Size and Forecast, By End User, 2021–2035
10.4.22. West Virginia
10.4.22.1. Overview
10.4.22.2. West Virginia Market Size and Forecast, By Offering, 2021–2035
10.4.22.3. West Virginia Market Size and Forecast, By Technology, 2021–2035
10.4.22.4. West Virginia Market Size and Forecast, By Application, 2021–2035
10.4.22.5. West Virginia Market Size and Forecast, By End User, 2021–2035
10.4.23. Delaware
10.4.23.1. Overview
10.4.23.2. Delaware Market Size and Forecast, By Offering, 2021–2035
10.4.23.3. Delaware Market Size and Forecast, By Technology, 2021–2035
10.4.23.4. Delaware Market Size and Forecast, By Application, 2021–2035
10.4.23.5. Delaware Market Size and Forecast, By End User, 2021–2035
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region IVD Assay Development Companies and Research Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
10.5.4. Midwest Region Market Size and Forecast, By Offering, 2021–2035
10.5.5. Midwest Region Market Size and Forecast, By Technology, 2021–2035
10.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035
10.5.8. Illinois
10.5.8.1. Overview
10.5.8.2. Illinois Market Size and Forecast, By Offering, 2021–2035
10.5.8.3. Illinois Market Size and Forecast, By Technology, 2021–2035
10.5.8.4. Illinois Market Size and Forecast, By Application, 2021–2035
10.5.8.5. Illinois Market Size and Forecast, By End User, 2021–2035
10.5.9. Ohio
10.5.9.1. Overview
10.5.9.2. Ohio Market Size and Forecast, By Offering, 2021–2035
10.5.9.3. Ohio Market Size and Forecast, By Technology, 2021–2035
10.5.9.4. Ohio Market Size and Forecast, By Application, 2021–2035
10.5.9.5. Ohio Market Size and Forecast, By End User, 2021–2035
10.5.10. Michigan
10.5.10.1. Overview
10.5.10.2. Michigan Market Size and Forecast, By Offering, 2021–2035
10.5.10.3. Michigan Market Size and Forecast, By Technology, 2021–2035
10.5.10.4. Michigan Market Size and Forecast, By Application, 2021–2035
10.5.10.5. Michigan Market Size and Forecast, By End User, 2021–2035
10.5.11. Minnesota
10.5.11.1. Overview
10.5.11.2. Minnesota Market Size and Forecast, By Offering, 2021–2035
10.5.11.3. Minnesota Market Size and Forecast, By Technology, 2021–2035
10.5.11.4. Minnesota Market Size and Forecast, By Application, 2021–2035
10.5.11.5. Minnesota Market Size and Forecast, By End User, 2021–2035
10.5.12. Indiana
10.5.12.1. Overview
10.5.12.2. Indiana Market Size and Forecast, By Offering, 2021–2035
10.5.12.3. Indiana Market Size and Forecast, By Technology, 2021–2035
10.5.12.4. Indiana Market Size and Forecast, By Application, 2021–2035
10.5.12.5. Indiana Market Size and Forecast, By End User, 2021–2035
10.5.13. Wisconsin
10.5.13.1. Overview
10.5.13.2. Wisconsin Market Size and Forecast, By Offering, 2021–2035
10.5.13.3. Wisconsin Market Size and Forecast, By Technology, 2021–2035
10.5.13.4. Wisconsin Market Size and Forecast, By Application, 2021–2035
10.5.13.5. Wisconsin Market Size and Forecast, By End User, 2021–2035
10.5.14. Missouri
10.5.14.1. Overview
10.5.14.2. Missouri Market Size and Forecast, By Offering, 2021–2035
10.5.14.3. Missouri Market Size and Forecast, By Technology, 2021–2035
10.5.14.4. Missouri Market Size and Forecast, By Application, 2021–2035
10.5.14.5. Missouri Market Size and Forecast, By End User, 2021–2035
10.5.15. Iowa
10.5.15.1. Overview
10.5.15.2. Iowa Market Size and Forecast, By Offering, 2021–2035
10.5.15.3. Iowa Market Size and Forecast, By Technology, 2021–2035
10.5.15.4. Iowa Market Size and Forecast, By Application, 2021–2035
10.5.15.5. Iowa Market Size and Forecast, By End User, 2021–2035
10.5.16. Kansas
10.5.16.1. Overview
10.5.16.2. Kansas Market Size and Forecast, By Offering, 2021–2035
10.5.16.3. Kansas Market Size and Forecast, By Technology, 2021–2035
10.5.16.4. Kansas Market Size and Forecast, By Application, 2021–2035
10.5.16.5. Kansas Market Size and Forecast, By End User, 2021–2035
10.5.17. Nebraska
10.5.17.1. Overview
10.5.17.2. Nebraska Market Size and Forecast, By Offering, 2021–2035
10.5.17.3. Nebraska Market Size and Forecast, By Technology, 2021–2035
10.5.17.4. Nebraska Market Size and Forecast, By Application, 2021–2035
10.5.17.5. Nebraska Market Size and Forecast, By End User, 2021–2035
10.5.18. North Dakota
10.5.18.1. Overview
10.5.18.2. North Dakota Market Size and Forecast, By Offering, 2021–2035
10.5.18.3. North Dakota Market Size and Forecast, By Technology, 2021–2035
10.5.18.4. North Dakota Market Size and Forecast, By Application, 2021–2035
10.5.18.5. North Dakota Market Size and Forecast, By End User, 2021–2035
10.5.19. South Dakota
10.5.19.1. Overview
10.5.19.2. South Dakota Market Size and Forecast, By Offering, 2021–2035
10.5.19.3. South Dakota Market Size and Forecast, By Technology, 2021–2035
10.5.19.4. South Dakota Market Size and Forecast, By Application, 2021–2035
10.5.19.5. South Dakota Market Size and Forecast, By End User, 2021–2035

What this section provides: This section delivers detailed four-region and 50-state analysis of the U.S. IVD assay development market, enabling clients to identify biotechnology clusters, diagnostic-development hubs, pharmaceutical activity, laboratory infrastructure, clinical-validation capacity and state-level commercialization opportunities.

11. U.S. IVD Assay Development Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Intensity Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Competitive Benchmarking
11.4.1. Assay Development Capabilities
11.4.2. Molecular Diagnostics Expertise
11.4.3. Clinical Validation Capabilities
11.4.4. Regulatory Expertise
11.4.5. Manufacturing and Design Transfer Capability
11.4.6. Companion Diagnostic Capability
11.4.7. Geographic Presence
11.5. Company Profiles
11.5.1. Thermo Fisher Scientific
11.5.2. Danaher Corporation
11.5.3. Roche Diagnostics
11.5.4. Abbott Laboratories
11.5.5. Siemens Healthineers
11.5.6. Becton, Dickinson and Company
11.5.7. bioMérieux
11.5.8. QuidelOrtho Corporation
11.5.9. Bio-Rad Laboratories
11.5.10. QIAGEN
11.5.11. Hologic
11.5.12. Illumina
11.5.13. Agilent Technologies
11.5.14. Bio-Techne Corporation
11.5.15. Revvity
11.5.16. Promega Corporation
11.5.17. Meridian Bioscience
11.5.18. LGC Clinical Diagnostics / SeraCare
11.5.19. Fujirebio Diagnostics
11.5.20. Maxim Biomedical
11.5.21. Avioq
11.5.22. Creative Biolabs
11.5.23. ICON plc
11.5.24. Labcorp
11.5.25. Quest Diagnostics

Note: Each company profile will include company overview, IVD assay development capabilities, relevant diagnostic technology portfolio, U.S. market strategy, molecular and companion diagnostic capabilities, clinical and regulatory expertise, partnerships, acquisitions, innovation pipeline and recent developments.

What this section provides: This section gives clients competitor benchmarking, capability positioning, market-share visibility, technology expertise and strategic intelligence on 25 companies participating in or influencing the U.S. IVD assay development ecosystem.

12. U.S. IVD Assay Development Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Next-Generation Sequencing
12.2.2. Digital PCR
12.2.3. Liquid Biopsy
12.2.4. Multi-Cancer Early Detection
12.2.5. CRISPR-Based Diagnostics
12.2.6. AI-Assisted Diagnostic Algorithms
12.2.7. Digital Pathology and Computational Biomarkers
12.2.8. Blood-Based Neurological Biomarkers
12.2.9. Point-of-Care Molecular Diagnostics
12.2.10. Fully Automated Sample-to-Answer Platforms
12.3. Emerging Business Trends
12.3.1. Pharma-Diagnostic Co-Development
12.3.2. Assay Development Outsourcing
12.3.3. Platform-Based Diagnostic Business Models
12.3.4. Biomarker Licensing
12.3.5. Laboratory Automation
12.3.6. Consolidation of Specialized Assay Developers
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Opportunity Matrix
12.7. Application Opportunity Matrix
12.8. State-Level Investment Opportunity Matrix

What this section provides: This section prepares clients for emerging diagnostic technologies, changing business models, outsourcing trends and investment opportunities that could reshape U.S. assay development through 2035.

13. U.S. IVD Assay Development Market: Strategic Recommendations

13.1. Recommendations for IVD and Diagnostic Manufacturers
13.2. Recommendations for Assay Development Service Providers
13.3. Recommendations for Pharmaceutical and Biotechnology Companies
13.4. Recommendations for Clinical and Reference Laboratories
13.5. Recommendations for CROs and CDMOs
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for New Entrants and Diagnostic Startups
13.8. Go-to-Market Strategy Considerations
13.9. Assay Pipeline Prioritization Guidance
13.10. Biomarker Commercialization Strategy
13.11. Regulatory and Clinical Evidence Strategy
13.12. Partnership and Licensing Strategy
13.13. U.S. Geographic Expansion Strategy
13.14. Product Positioning and Portfolio Expansion Guidance

What this section provides: This section converts market intelligence into actionable strategies for assay pipeline development, regulatory planning, biomarker commercialization, outsourcing, geographic expansion, investment allocation and competitive differentiation.

14. U.S. IVD Assay Development Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Estimation Limitation
14.4. Forecasting Limitation
14.5. Regulatory Information Limitation
14.6. Legal Disclaimer
14.7. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope limitations, market-estimation boundaries, forecasting assumptions, regulatory information limitations, third-party data usage and applicable legal considerations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. IVD Assay Development Market: Market Definition and Scope
TABLE 3: U.S. IVD Assay Development Market: Research Methodology Framework
TABLE 4: U.S. IVD Assay Development Market: Key Assumptions
TABLE 5: U.S. IVD Assay Development Market: Market Ecosystem Overview
TABLE 6: U.S. IVD Assay Development Market: Stakeholder Analysis
TABLE 7: U.S. IVD Assay Development Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. IVD Assay Development Market: Analyst Viewpoint Summary
TABLE 9: U.S. IVD Assay Development Market: Market Attractiveness Index
TABLE 10: U.S. IVD Assay Development Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. IVD Assay Development Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. IVD Assay Development Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. IVD Assay Development Market: High-Growth Opportunity Areas
TABLE 14: U.S. IVD Assay Development Market: Drivers; Impact Analysis
TABLE 15: U.S. IVD Assay Development Market: Restraints; Impact Analysis
TABLE 16: U.S. IVD Assay Development Market: Opportunities; Impact Analysis
TABLE 17: U.S. IVD Assay Development Market: Challenges; Impact Analysis
TABLE 18: U.S. IVD Assay Development Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. IVD Assay Development Market: Diagnostic Laboratory Workflow Economics Matrix
TABLE 20: U.S. IVD Assay Development Market: Assay Development Cost Structure Analysis
TABLE 21: U.S. IVD Assay Development Market: Outsourcing vs. In-House Development Matrix
TABLE 22: U.S. IVD Assay Development Market: Biomarker-to-Commercial Assay Conversion Analysis
TABLE 23: U.S. IVD Assay Development Market: PESTEL Analysis
TABLE 24: U.S. IVD Assay Development Market: Porter’s Five Forces Analysis
TABLE 25: U.S. IVD Assay Development Market: Assay Development Pricing Trends, 2025–2035
TABLE 26: U.S. IVD Assay Development Market: Value Chain Analysis
TABLE 27: U.S. IVD Assay Development Market: Supply Chain Analysis
TABLE 28: U.S. IVD Assay Development Market: Biomarker Discovery-to-Commercialization Value Chain
TABLE 29: U.S. IVD Assay Development Market: Application & Innovation Landscape
TABLE 30: U.S. IVD Assay Development Market: FDA IVD Regulatory Framework
TABLE 31: U.S. IVD Assay Development Market: 510(k), De Novo and PMA Pathway Comparison
TABLE 32: U.S. IVD Assay Development Market: Companion Diagnostic Regulatory Considerations
TABLE 33: U.S. IVD Assay Development Market: CLIA and Laboratory Testing Framework
TABLE 34: U.S. IVD Assay Development Market: CMS Reimbursement and Coverage Landscape
TABLE 35: U.S. IVD Assay Development Market: CPT and PLA Coding Considerations
TABLE 36: U.S. IVD Assay Development Market: Quality System and Design Control Requirements
TABLE 37: U.S. IVD Assay Development Market: Reference Materials and Analytical Standards Landscape
TABLE 38: U.S. IVD Assay Development Market: AI, Bioinformatics and Laboratory Automation Impact
TABLE 39: U.S. IVD Assay Development Market: Import, Tariff and Supply-Chain Risk Analysis
TABLE 40: U.S. IVD Assay Development Market: Government Initiatives and Public Health Programs
TABLE 41: U.S. IVD Assay Development Market: Diagnostic Commercialization Decision Framework
TABLE 42: U.S. IVD Assay Development Market: Offering Snapshot, 2025
TABLE 43: Segment Dashboard; Definition and Scope, by Offering
TABLE 44: U.S. IVD Assay Development Market, by Offering, 2021–2035 (US$ Billion)
TABLE 45: U.S. IVD Assay Development Market: Segment Share Analysis, by Offering, 2025 & 2035 (%)
TABLE 46: IVD Assay Development Services Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: IVD Assay Stability Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Packaging and Design Transfer Services Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: Regulatory, Validation and Quality Support Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: Technology Transfer and Custom QA/QC Services Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. IVD Assay Development Market: Technology Snapshot, 2025
TABLE 52: Segment Dashboard; Definition and Scope, by Technology
TABLE 53: U.S. IVD Assay Development Market, by Technology, 2021–2035 (US$ Billion)
TABLE 54: U.S. IVD Assay Development Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 55: Immunoassay and Immunochemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Molecular Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Clinical Chemistry and Biochemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: Hematology and Coagulation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: Microbiology and Urinalysis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. IVD Assay Development Market: Molecular Technology Opportunity Matrix
TABLE 61: U.S. IVD Assay Development Market: Application Snapshot, 2025
TABLE 62: Segment Dashboard; Definition and Scope, by Application
TABLE 63: U.S. IVD Assay Development Market, by Application, 2021–2035 (US$ Billion)
TABLE 64: U.S. IVD Assay Development Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 65: Infectious Diseases Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: Oncology Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: Diabetes and Metabolic Disease Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: Cardiology Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Neurology, Nephrology, Reproductive Health and Other Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. IVD Assay Development Market: Companion Diagnostic Opportunity Analysis
TABLE 71: U.S. IVD Assay Development Market: Liquid Biopsy and Multi-Cancer Detection Opportunity Analysis
TABLE 72: U.S. IVD Assay Development Market: End User Snapshot, 2025
TABLE 73: Segment Dashboard; Definition and Scope, by End User
TABLE 74: U.S. IVD Assay Development Market, by End User, 2021–2035 (US$ Billion)
TABLE 75: U.S. IVD Assay Development Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 76: IVD and Diagnostic Manufacturers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: Biotechnology and Pharmaceutical Companies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Clinical and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: Academic Medical Centers and Research Institutions Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: Contract Research, Development and Manufacturing Organizations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. IVD Assay Development Market: End-User Outsourcing Behavior Matrix
TABLE 82: U.S. IVD Assay Development Market: Biomarker Discovery and Target Selection Framework
TABLE 83: U.S. IVD Assay Development Market: Assay Feasibility and Proof-of-Concept Framework
TABLE 84: U.S. IVD Assay Development Market: Prototype Development and Analytical Optimization Matrix
TABLE 85: U.S. IVD Assay Development Market: Analytical Verification Requirements
TABLE 86: U.S. IVD Assay Development Market: Analytical Validation Parameters
TABLE 87: U.S. IVD Assay Development Market: Clinical Validation and Performance Study Framework
TABLE 88: U.S. IVD Assay Development Market: Design Transfer and Manufacturing Scale-Up Matrix
TABLE 89: U.S. IVD Assay Development Market: Regulatory Submission Strategy Matrix
TABLE 90: U.S. IVD Assay Development Market: Laboratory Workflow Integration Framework
TABLE 91: U.S. IVD Assay Development Market: Reimbursement and Commercial Launch Readiness Matrix
TABLE 92: U.S. IVD Assay Development Market: Typical Development Timeline Analysis
TABLE 93: U.S. IVD Assay Development Market: Development Cost and Outsourcing Economics
TABLE 94: U.S. IVD Assay Development Market: Regional Snapshot, 2025
TABLE 95: Segment Dashboard; Definition and Scope, by Geography
TABLE 96: U.S. IVD Assay Development Market, by Region, 2021–2035 (US$ Billion)
TABLE 97: U.S. IVD Assay Development Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 98: U.S. IVD Assay Development Market: Regional Diagnostic and Biotechnology Ecosystem
TABLE 99: U.S. IVD Assay Development Market: Regional Clinical Laboratory Infrastructure
TABLE 100: West Region U.S. IVD Assay Development Market: Regional Overview and Trends
TABLE 101: West Region U.S. IVD Assay Development Market: Assay Development and Research Ecosystem
TABLE 102: West Region U.S. IVD Assay Development Market, by State, 2021–2035 (US$ Billion)
TABLE 103: West Region U.S. IVD Assay Development Market, by Offering, 2021–2035 (US$ Billion)
TABLE 104: West Region U.S. IVD Assay Development Market, by Technology, 2021–2035 (US$ Billion)
TABLE 105: West Region U.S. IVD Assay Development Market, by Application, 2021–2035 (US$ Billion)
TABLE 106: West Region U.S. IVD Assay Development Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: California IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Washington IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Arizona IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Colorado IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Oregon IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Utah IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Nevada IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: New Mexico IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Idaho IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Montana IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Wyoming IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Alaska IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Hawaii IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Northeast Region U.S. IVD Assay Development Market: Regional Overview and Trends
TABLE 121: Northeast Region U.S. IVD Assay Development Market: Assay Development and Research Ecosystem
TABLE 122: Northeast Region U.S. IVD Assay Development Market, by State, 2021–2035 (US$ Billion)
TABLE 123: Northeast Region U.S. IVD Assay Development Market, by Offering, 2021–2035 (US$ Billion)
TABLE 124: Northeast Region U.S. IVD Assay Development Market, by Technology, 2021–2035 (US$ Billion)
TABLE 125: Northeast Region U.S. IVD Assay Development Market, by Application, 2021–2035 (US$ Billion)
TABLE 126: Northeast Region U.S. IVD Assay Development Market, by End User, 2021–2035 (US$ Billion)
TABLE 127: New York IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Massachusetts IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: New Jersey IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Pennsylvania IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Connecticut IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Maine IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Vermont IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: New Hampshire IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Rhode Island IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: South Region U.S. IVD Assay Development Market: Regional Overview and Trends
TABLE 137: South Region U.S. IVD Assay Development Market: Assay Development and Research Ecosystem
TABLE 138: South Region U.S. IVD Assay Development Market, by State, 2021–2035 (US$ Billion)
TABLE 139: South Region U.S. IVD Assay Development Market, by Offering, 2021–2035 (US$ Billion)
TABLE 140: South Region U.S. IVD Assay Development Market, by Technology, 2021–2035 (US$ Billion)
TABLE 141: South Region U.S. IVD Assay Development Market, by Application, 2021–2035 (US$ Billion)
TABLE 142: South Region U.S. IVD Assay Development Market, by End User, 2021–2035 (US$ Billion)
TABLE 143: Texas IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Florida IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Georgia IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: North Carolina IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Tennessee IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: South Carolina IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Alabama IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Mississippi IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Louisiana IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Arkansas IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Kentucky IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Oklahoma IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Virginia IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Maryland IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: West Virginia IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Delaware IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Midwest Region U.S. IVD Assay Development Market: Regional Overview and Trends
TABLE 160: Midwest Region U.S. IVD Assay Development Market: Assay Development and Research Ecosystem
TABLE 161: Midwest Region U.S. IVD Assay Development Market, by State, 2021–2035 (US$ Billion)
TABLE 162: Midwest Region U.S. IVD Assay Development Market, by Offering, 2021–2035 (US$ Billion)
TABLE 163: Midwest Region U.S. IVD Assay Development Market, by Technology, 2021–2035 (US$ Billion)
TABLE 164: Midwest Region U.S. IVD Assay Development Market, by Application, 2021–2035 (US$ Billion)
TABLE 165: Midwest Region U.S. IVD Assay Development Market, by End User, 2021–2035 (US$ Billion)
TABLE 166: Illinois IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Ohio IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Michigan IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: Minnesota IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Indiana IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Wisconsin IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 172: Missouri IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 173: Iowa IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 174: Kansas IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 175: Nebraska IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 176: North Dakota IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 177: South Dakota IVD Assay Development Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 178: U.S. IVD Assay Development Market: Competitive Landscape Snapshot, 2025
TABLE 179: U.S. IVD Assay Development Market: Key Company Market Share Analysis, 2025
TABLE 180: U.S. IVD Assay Development Market: Company Positioning Matrix
TABLE 181: U.S. IVD Assay Development Market: Competitive Capability Benchmarking
TABLE 182: U.S. IVD Assay Development Market: Strategic Developments, Partnerships, M&A and Assay Launches
TABLE 183: Thermo Fisher Scientific: Company Profile
TABLE 184: Danaher Corporation: Company Profile
TABLE 185: Roche Diagnostics: Company Profile
TABLE 186: Abbott Laboratories: Company Profile
TABLE 187: Siemens Healthineers: Company Profile
TABLE 188: Becton, Dickinson and Company: Company Profile
TABLE 189: bioMérieux: Company Profile
TABLE 190: QuidelOrtho Corporation: Company Profile
TABLE 191: Bio-Rad Laboratories: Company Profile
TABLE 192: QIAGEN: Company Profile
TABLE 193: Hologic: Company Profile
TABLE 194: Illumina: Company Profile
TABLE 195: Agilent Technologies: Company Profile
TABLE 196: Bio-Techne Corporation: Company Profile
TABLE 197: Revvity: Company Profile
TABLE 198: Promega Corporation: Company Profile
TABLE 199: Meridian Bioscience: Company Profile
TABLE 200: LGC Clinical Diagnostics / SeraCare: Company Profile
TABLE 201: Fujirebio Diagnostics: Company Profile
TABLE 202: Maxim Biomedical: Company Profile
TABLE 203: Avioq: Company Profile
TABLE 204: Creative Biolabs: Company Profile
TABLE 205: ICON plc: Company Profile
TABLE 206: Labcorp: Company Profile
TABLE 207: Quest Diagnostics: Company Profile
TABLE 208: U.S. IVD Assay Development Market: Future Market Scenario Analysis, 2026–2035
TABLE 209: U.S. IVD Assay Development Market: Disruptive Technologies Impact Matrix
TABLE 210: U.S. IVD Assay Development Market: NGS, Digital PCR and Liquid Biopsy Opportunity Matrix
TABLE 211: U.S. IVD Assay Development Market: AI and Computational Diagnostic Opportunity Matrix
TABLE 212: U.S. IVD Assay Development Market: Emerging Business Trends
TABLE 213: U.S. IVD Assay Development Market: Business Opportunities for Startups and Existing Players
TABLE 214: U.S. IVD Assay Development Market: Investment Prioritization Matrix
TABLE 215: U.S. IVD Assay Development Market: State-Level Investment Opportunity Matrix
TABLE 216: U.S. IVD Assay Development Market: Strategic Recommendations for IVD Manufacturers
TABLE 217: U.S. IVD Assay Development Market: Strategic Recommendations for Assay Development Service Providers
TABLE 218: U.S. IVD Assay Development Market: Strategic Recommendations for Pharmaceutical and Biotechnology Companies
TABLE 219: U.S. IVD Assay Development Market: Strategic Recommendations for Clinical and Reference Laboratories
TABLE 220: U.S. IVD Assay Development Market: Strategic Recommendations for CROs and CDMOs
TABLE 221: U.S. IVD Assay Development Market: Strategic Recommendations for Investors and New Entrants
TABLE 222: U.S. IVD Assay Development Market: Go-to-Market and Assay Pipeline Prioritization Framework
TABLE 223: U.S. IVD Assay Development Market: Biomarker Commercialization and Partnership Strategy
TABLE 224: U.S. IVD Assay Development Market: Scope Limitation
TABLE 225: U.S. IVD Assay Development Market: Data Use Limitation
TABLE 226: U.S. IVD Assay Development Market: Market Estimation Limitation
TABLE 227: U.S. IVD Assay Development Market: Forecasting Limitation
TABLE 228: U.S. IVD Assay Development Market: Regulatory Information Limitation
TABLE 229: U.S. IVD Assay Development Market: Legal Disclaimer
TABLE 230: U.S. IVD Assay Development Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. IVD Assay Development Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. IVD Assay Development Market Ecosystem
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: U.S. IVD Assay Development Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. IVD Assay Development Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. IVD Assay Development Market Year-wise Growth Curve, 2021–2035
FIGURE 8: U.S. IVD Assay Development Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Diagnostic Laboratory Workflow Economics Framework
FIGURE 11: Assay Development Cost Structure
FIGURE 12: Outsourcing vs. In-House Assay Development Decision Framework
FIGURE 13: PESTEL Analysis
FIGURE 14: Porter’s Five Forces Analysis
FIGURE 15: Value Chain Analysis
FIGURE 16: Supply Chain Analysis
FIGURE 17: Biomarker Discovery-to-Commercialization Pathway
FIGURE 18: FDA IVD Regulatory Pathway Framework
FIGURE 19: CLIA, Reimbursement and Commercialization Framework
FIGURE 20: AI, Bioinformatics and Laboratory Automation Impact
FIGURE 21: Offering Segment Market Share Analysis, 2025 & 2035
FIGURE 22: Offering Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: IVD Assay Development Services Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 24: IVD Assay Stability Testing Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 25: Packaging and Design Transfer Services Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 26: Regulatory, Validation and Quality Support Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 27: Technology Transfer and Custom QA/QC Services Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 28: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 29: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Immunoassay and Immunochemistry Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 31: Molecular Diagnostics Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 32: Clinical Chemistry and Biochemistry Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 33: Hematology and Coagulation Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 34: Microbiology and Urinalysis Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 35: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 36: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Infectious Diseases Assay Development Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 38: Oncology Assay Development Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 39: Diabetes and Metabolic Disease Assay Development Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 40: Cardiology Assay Development Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 41: Neurology, Nephrology, Reproductive Health and Other Applications Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 42: Companion Diagnostics and Liquid Biopsy Opportunity Map
FIGURE 43: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 44: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: IVD and Diagnostic Manufacturers Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 46: Biotechnology and Pharmaceutical Companies Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 47: Clinical and Reference Laboratories Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 48: Academic Medical Centers and Research Institutions Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 49: Contract Research, Development and Manufacturing Organizations Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 50: Biomarker Discovery-to-Assay Feasibility Roadmap
FIGURE 51: Analytical Verification and Validation Framework
FIGURE 52: Clinical Validation and Performance Study Framework
FIGURE 53: Design Transfer and Manufacturing Scale-Up Roadmap
FIGURE 54: Regulatory Submission and Commercial Launch Roadmap
FIGURE 55: IVD Assay Development Timeline and Cost Curve
FIGURE 56: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 57: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: West Region U.S. IVD Assay Development Market Share and Leading Players, 2025
FIGURE 59: West Region Market Share Analysis by State, 2025
FIGURE 60: California IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 61: Washington IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 62: Arizona IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 63: Colorado IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 64: Oregon IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: Utah IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Nevada IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: New Mexico IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: Idaho IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: Montana IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Wyoming IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: Alaska IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Hawaii IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: Northeast Region U.S. IVD Assay Development Market Share and Leading Players, 2025
FIGURE 74: Northeast Region Market Share Analysis by State, 2025
FIGURE 75: New York IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 76: Massachusetts IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 77: New Jersey IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 78: Pennsylvania IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: Connecticut IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 80: Maine IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 81: Vermont IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 82: New Hampshire IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Rhode Island IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: South Region U.S. IVD Assay Development Market Share and Leading Players, 2025
FIGURE 85: South Region Market Share Analysis by State, 2025
FIGURE 86: Texas IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: Florida IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 88: Georgia IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 89: North Carolina IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 90: Tennessee IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 91: South Carolina IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 92: Alabama IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: Mississippi IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: Louisiana IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: Arkansas IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: Kentucky IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: Oklahoma IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Virginia IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: Maryland IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: West Virginia IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Delaware IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Midwest Region U.S. IVD Assay Development Market Share and Leading Players, 2025
FIGURE 103: Midwest Region Market Share Analysis by State, 2025
FIGURE 104: Illinois IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Ohio IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 106: Michigan IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 107: Minnesota IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 108: Indiana IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 109: Wisconsin IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: Missouri IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: Iowa IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: Kansas IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 113: Nebraska IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 114: North Dakota IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 115: South Dakota IVD Assay Development Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 116: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 117: Company Positioning Matrix
FIGURE 118: Key Player Assay Development Capability Benchmarking
FIGURE 119: Strategic Developments, Partnerships, M&A and Assay Launches
FIGURE 120: Competitive Innovation and Commercialization Roadmap
FIGURE 121: Future Market Scenario Analysis, 2026–2035
FIGURE 122: Disruptive Technologies Impact Matrix
FIGURE 123: NGS, Digital PCR and Liquid Biopsy Opportunity Map
FIGURE 124: AI and Computational Diagnostics Growth Roadmap
FIGURE 125: Investment Prioritization Matrix
FIGURE 126: Strategic Growth Roadmap for U.S. IVD Assay Development Companies
FIGURE 127: Go-to-Market and Assay Pipeline Prioritization Framework
FIGURE 128: Biomarker Commercialization, Partnership and Licensing Framework
FIGURE 129: Report Scope and Disclaimer Framework